Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform.

The investment firm said it believes TRACER alone should be a valuable asset, noting “initial novel AAV capsid candidates from the platform have demonstrated significantly